Genmab and AbbVie's sBLA for Epkinly Granted FDA Priority Review for Relapsed/Refractory Follicular Lymphoma

MEEFRO February 27, 2024

0 124,533 Less than a minute

Epkinly (epcoritamab-bysp) is a subcutaneously administered, T-cell engaging, immunoglobulin G1-bispecific antibody under evaluation for aggressive B-cell lymphomas.

Source link
#Genmab #AbbVie039s #sBLA #Epkinly #Granted #FDA #Priority #Review #RelapsedRefractory #Follicular #Lymphoma